Growth hormone-releasing hormone (GHRH) is secreted by the hypothalamus and acts on the pituitary gland to stimulate the release of growth hormone (GH). GHRH can also be produced by human cancers, in which it functions as an autocrine/paracrine growth factor. We have previously shown that synthetic antagonistic analogues of GHRH are able to successfully suppress the growth of 60 different human cancer cell lines representing over 20 cancers. Nevertheless, the expression of GHRH and its receptors in leukaemias has never been examined. Our study demonstrates the presence of GHRH receptor (GHRH-R) on 3 of 4 human acute myeloid leukaemia (AML) cell lines-K-562, THP-1, and KG-1a-and significant inhibition of proliferation of these three cell lines in vitro following incubation with the GHRH antagonist MIA-602. We further show that this inhibition of proliferation is associated with the upregulation of pro-apoptotic genes and inhibition of Akt signalling in leukaemic cells. Treatment with MIA-602 of mice bearing xenografts of these human AML cell lines drastically reduced tumour growth. The expression of GHRH-R was further confirmed in 9 of 9 samples from patients with AML. These findings offer a new therapeutic approach to this malignancy and suggest a possible role of GHRH-R signalling in the pathology of AML.
Acute myeloid leukaemia (AML) is a disorder of the blood and bone marrow, characterized by a series of mutagenic events leading to the uncontrolled proliferation of myeloid precursor cells. The prognosis for this disease is often poor, with a 5-year survival rate of approximately 27% (Howlader et al, 2017) . Current clinical therapies for AML consist of chemotherapeutic regimens, or in more severe cases, bone marrow stem cell transplantation (D€ ohner et al, 2015) . Overall, standard AML treatments have seen little change; moreover, traditional approaches have been associated with elevated morbidity and mortality rates as a consequence of frequent relapses and implicit toxicity. In particular, bone marrow transplantation carries with it the ever-present risks of graft-versus-host disease (GVHD) and a host of other pulmonary and hepatic complications (Gooley et al, 2010) . As such, there is a great need for exploration of novel alternative therapeutic approaches for AML. One approach that has not been previously attempted in this disease but has shown substantial efficacy in other cancers is anti-hormonal therapy, particularly the use of peptide analogues.
We have developed various peptide analogues of growth hormone-releasing hormone (GHRH), both agonistic and antagonistic (Zarandi et al, 1994 (Zarandi et al, , 2017 Schally et al, 2008) . GHRH is secreted by the hypothalamus and acts on the pituitary to stimulate the synthesis and the release of growth hormone (GH) . Because only extremely small quantities of GHRH are present in the hypothalamus, it was initially not possible to characterize hypothalamic GHRH structurally until the early 1980s (Guillemin et al, 1982; Rivier et al, 1982) . The 44-and 40-amino acid forms of GHRH were first isolated and structurally characterized from human pancreatic tumours (Guillemin et al, 1982; Rivier et al, 1982) and only subsequently identified in animal and human hypothalami. Thus, GHRH can be produced by tumours themselves, in which it functions in an autocrine/ paracrine fashion as a growth factor (Kov acs et al, 2008; Schally et al, 2008) . Subsequently, the presence of GHRH and the expression of the its gene (GHRH) were demonstrated in several extrahypothalamic tissues, including placenta, ovary, testis, digestive tract and tumours, suggesting that GHRH might have a role in these tissues (Kah an et al, 1999; Schally et al, 2008) . GHRH mRNA was found in surgical specimens of human prostate, breast, ovarian, endometrial, adrenal and pancreatic cancers, and human cancer lines derived from breast, endometrial, ovarian, prostatic, pancreatic, gastric, colorectal, lung and brain tissue, bone sarcomas, lymphomas and renal-cell carcinomas (Kah an et al, 1999; Schally et al, 2008) .
Growth hormone-releasing hormone peptide has been detected in breast surgical specimens of human, endometrial, ovarian, colorectal, gastric, pancreatic and lung cancers, lymphomas and in corresponding human cancer lines. Furthermore, the proliferation in vitro of many cancer cell lines is stimulated by exogenous GHRH. The presence of biologically active GHRH and GHRH mRNA in various cancers supports the view that locally produced GHRH functions as an autocrine growth factor in the proliferation of these tumours . This expression of GHRH receptors on these tumours provides the basis for a new approach to the treatment of cancer based on antagonists of GHRH . The pituitary GHRH-R (pGHRH-R) is a seventransmembrane-domain receptor coupled to G-protein (Rekasi et al, 2000; Schulz et al, 2006; Schally et al, 2008) . Truncated splice variants (SV) of GHRH receptors and pituitary-type GHRH receptor, as well as, are expressed in various normal human tissues-e.g., the prostate, kidney, lung and liver-as well as on most human cancer cell lines and tumours (Rekasi et al, 2000; Schulz et al, 2006) . The SV1 receptor differs from pGHRH-R only in the amino-terminal extracellular domain, where a 25-amino-acid sequence replaces the first 89 amino acids of pGHRH-R (Rekasi et al, 2000) . Polymerase chain reaction (PCR) analyses and Western blots have revealed the expression of GHRH-R SVs in several cancers, including prostatic, pancreatic, bone sarcomas, glioblastomas and lymphomas (Rekasi et al, 2000; Schulz et al, 2006) . We produced nearly 2000 synthetic antagonistic analogues of GHRH, improving their potency and half-life by substituting some of the natural (coded) Lamino acids in the biologically active N-terminal 29 amino acid sequence of GHRH either with their "D" isomers or with synthetic amino acids (Zarandi et al, 1994 (Zarandi et al, , 2017 Schally et al, 2008) . These GHRH antagonists have been shown to block the growth of 60 human cell lines xenografted into nude mice, with undetectable side effects . These xenografts represent over 20 different human tumour types, including cancers of the prostate, kidney, bladder, breast, ovary, esophagus, stomach, colon, lung, and uterus, astrocytomas, melanomas, pheochromocytomas, osteosarcomas and multiple lymphoma types (Pinski et al, 1995; Jungwirth et al, 1997; Kiaris & Schally, 1999; Szepeshazi et al, 2000a,b; Chatzistamou et al, 2001a,b; Schally et al, 2004 Schally et al, , 2015 Schally, 2008; Rick et al, 2012; Gan et al, 2016) . The GHRH antagonist MIA-602, representing the latest series of analogues synthesized, has been chosen for further clinical development (Rick et al, 2012; Schally et al, 2015; Gan et al, 2016; Zarandi et al, 2017) . Considering the previously stated role of GHRH in multiple cancers, these small-peptide GHRH antagonists provide a promising approach for targeted leukaemia therapy, which could be more efficacious and better-tolerated than the current regimens.
In the current study, we investigated the effects of GHRH antagonists MIA-602 in four human AML lines both in vitro and in vivo, as well as the expression of GHRH receptors in both cell lines and primary patient samples.
Methods

Peptides and reagents
Growth hormone-releasing hormone antagonist MIA-602 was synthesized by solid phase method and purified by reversed-phase high performance liquid chromatography (HPLC) as described previously (Zarandi et al, 1994 (Zarandi et al, , 2017 
Cell proliferation
Cells were seeded onto 12-well microplates at a density of 2Á5 9 10 5 cells/ml in their corresponding media supplemented with 1% FBS, 2 mmol/l L-glutamine, 25 mmol/l HEPES, and 50 lg/ml gentamicin. Cells were treated with MIA-602 at concentrations of 0Á05, 0Á5 and 5 lmol/l for 24 and 48 h. Each treatment was performed in quadruplicate. Cell proliferation was evaluated by using the MOXI Mini Automated Cell Counter (Orflo Technologies, Ketchum, ID, USA).
Total RNA isolation and RT 2 profiler PCR array human cells death pathway finder Cells were seeded into 25 cm 2 flask at a density of 2Á5 9 10 5 cells/ml in the corresponding media supplemented with 2 mmol/l L-glutamine, 25 mmol/l HEPES, 1% FBS and 50 lg/ml gentamicin, with or without treatment with 5 lmol/l MIA-602 for 24 h. For each cell line, total RNA was isolated from 3Á5 9 10 6 cells using RNaesy Mini Kit (Qiagen Ltd., Hilden, Germany) according to manufacturer instructions. RNA (0Á5 lg) in a final volume of 20 ll was reverse transcribed into cDNA using RT 2 First Strand Kit (Qiagen Ltd.) Human Cell Death Pathway Finder RT 2 Profiler PCR Array (SABiosciences, Corp., Frederick, MD, USA) was used to analyse the expression of 84 selected genes. The real-time PCR (qPCR) was performed using 30 ng of cDNA per well in a Bio-Rad Real Time PCR System (Bio-Rad, Hercules, CA, USA) as follows: one cycle of 10 min at 95°C, followed by 40 cycles of 15 s at 95°C, and 1 min at 60°C. Raw data was analysed using the web-based automated software for RT 2 Profiler PCR Array Data Analysis. Fold-changes in gene expression were calculated using ΔΔCt method. Normalization was performed using five housekeeping genes on the array. Genes that are significantly up regulated or downregulated by MIA-602 treatment, with at least a 2-fold difference compared to control, are shown. Significance was determined by two-tailed Student's t-test.
Apoptosis assay
Apoptosis rates were determined with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) method (DeadEnd TM Fluorometric TUNEL System Protocol, Promega, Madison, WI, USA) using a fluorescent microscope according to manufacturer instructions. Subsequently the numbers of apoptotic and live cells were determined.
In vivo experiments in mice
Eight-week-old female athymic nude mice (Hsd: Athymic Nude-Foxn1^nu), obtained from Harlan Laboratories (Indianapolis, IN), were housed in sterile cages in a temperaturecontrolled room with a 12-h light\12-h dark schedule. Mice were fed autoclaved chow and water ad libitum. Xenografts of human myeloid leukaemia cells KG-1, KG-1a, K-562 and THP-1 were initiated by subcutaneous (s.c.) injection of 1 9 10 7 cells into the right flank of nude mice. For each cell line, once tumours reached an appropriate size (approx. 40 mm 3 ), mice were randomly divided into two groups of 15 animals each, receiving s.c. injections into the left flank, twice a day, of PBS (100 ll) containing 0Á1% DMSO or MIA-602 at a dose of 10 lg, depending on group assignment. Tumour volume (length 9 width 9 height 9 0Á5236) and body weight were measured every 7 days for a total of 28 days. 
Patient samples
Primary AML samples were collected by the Tissue Banking Core Facility at the University of Miami/Sylvester Comprehensive Cancer Center according to the Institutional Review Board-approved protocol (20060858) . Bone marrow aspirates were subjected to Ficoll (Ficoll Paque Plus, GE Healthcare Bio-Sciences, Pittsburgh, PA, USA) density gradient centrifugation to purify the mononuclear fraction. Expression of GHRH, GHRH-R and SV1 in patient samples (1-9) was determined based on Western blots acquired using two series of cell lysates: if a band was visual by eye in any of the detection/contrast setups used in at least one of the two experiments, the sample was determined to be positive.
Statistical analysis
For statistical evaluation, GraphPad Prism 6 software (GraphPad Software, San Diego, CA, USA) was used. Results are expressed as means AE standard error of the mean (SEM). One-way analysis of variance (ANOVA) followed by Dunnett post-hoc test was used and significance accepted at P < 0Á05.
Results
To assess the feasibility of targeted therapy of GHRH-R in myeloid leukaemia, we first determined the expression of pGHRH-R and its SV1 variant in human leukaemic cell lines. The antibody used to detect GHRH receptor by Western blot was raised against a C-terminal portion of the protein that is present in the pituitary type GHRH-R and the SV1 splice variant but not in other splice variants, selectively recognizing these most important cancer-related forms. The pGHRH-R appears at 47 kDa when not glycosylated and between 50 and 60 kDa when glycosylated. SV1 appears as a single or double band at approximately 40 kDa (Schulz et al, 2006) . K562, THP-1, KG-1 and its subclone, KG-1a, have each been used previously to model acute myeloid leukaemia (Havt et al, 2005; Fuchs & Steller, 2011; Daver & Cortes, 2013; Chu et al, 2016; Coombs et al, 2016) . K-562 expressed both the pituitary type and SV1 receptors, THP-1 cells only pGHRH-R, the subclone KG-1a both SV1 and low levels of pGHRH-R, and the parental KG-1 cell line expressed neither type (Fig 1A) . This expression pattern was confirmed by immunocytochemistry ( Fig 1B) . Based on these results, we hypothesized that K-562, THP-1 and KG-1a cells could respond to GHRH antagonists, whereas the KG-1 cells, which would not respond, could serve as a negative control.
We next grew KG-1, KG-1a, K-562 and THP-1 cells in the presence of 0Á05 to 5 lmol/l MIA-602 for 24 and 48 h. Treatment with MIA-602 induced a significant dose-and time-dependent reduction in cell proliferation in the three GHRH-R-positive cell lines, but not in KG-1. Thus, MIA-602 induced a robust decrease in cell proliferation at 5 lmol/l concentration, which was over 50% at 24 h, and approximately 80% at 48 h in K-562 and KG-1a cells (Fig 1C, D) . The reduction in cell proliferation was smaller in THP-1 cells, which express only the pituitary-type receptor, amounting to 32Á7% at 24 h and 50Á4% at 48 h. Cell growth in the GHRH-R-negative KG-1 line was not changed by MIA-602 at 24 h and only slightly decreased after 48 h (Fig 1D) . Notably, the relative reduction in the proliferation rate in KG-1a suggested that blocking SV1 with the antagonist MIA-602 produces a superior anti-proliferative effect than antagonizing the pGHRH-R alone.
Using a panel of 84 death-related genes, we further determined that MIA-602 functions in these cell lines principally by activating pro-apoptotic pathways. In KG-1a cells, MIA-602 induced significant changes (≥2 fold; P < 0Á05) in the expression level of 16 death-related genes: in particular, the pro-apoptotic gene IFNG was upregulated 28Á87-fold (P < 0Á05) (Fig 2D) . MIA-602 also significantly increased expression of CASP9 (2Á08-fold; P < 0Á05), CD40LG (3Á72-fold; P < 0Á05), HTT (2Á25-fold; P < 0Á05), and MCL1 (2Á15-fold; P < 0Á01) (Fig 2B) in THP-1 cells. Although the first three genes (CASP9, CD40LG, and HTT) are more pro-apoptotic in nature, only select isoforms of the MCL1 protein encourage apoptosis. In K-562 cells, the GHRH antagonist induced the upregulation of the pro-apoptotic gene TNF (2Á16-fold; P < 0Á01) (Fig 2C) .
MIA-602 also induced changes in gene expression in the KG-1 cell line. After 24 h of treatment with MIA-602, there was a significant increase in the expression of both BIRC3 (4Á64-fold; P < 0Á01) and TNF (4Á11-fold; P < 0Á01) (Fig 2A) . This result is most probably due to the heterogeneity of cancer cell populations, since at least one KG-1 subclone (i.e., KG-1a) responds to GHRH-R blockade. Therefore, some response to MIA-602 could result from subclones within the KG-1 population.
Previous studies performed on solid tumours have shown that the cell signalling pathways involved in the anti-proliferative effect induced by GHRH antagonists include MAPK/ Erk(1/2) and/or P13K/Akt (Chatzistamou et al, 2001a; Schally et al, 2008) . Protein expression analyses in the GHRH-R positive K562, THP-1 and KG-1a lines revealed that phosphorylation of the serine/threonine protein kinase Akt after 8 h incubation with MIA-602 is decreased dramatically in K-562 and KG-1a lines and notably in THP-1 (Fig 2e-h) . A concomitant increase in cleaved caspase 3 was also observed, indicating activation of the apoptotic pathway.
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Conversely, none of these changes were found in the KG-1 cells. The percentage of apoptotic cells after 48-h treatment with 5 lmol/l MIA-602 was also measured by TUNEL. For THP-1 cells, untreated cells showed 2% apoptosis (SEM = 1%), whereas MIA-602-treated showed 51% (SEM = 2Á5%). For both KG1a cells and K562 cells, apoptosis in the control condition was 1% (SEM = 0Á5%) and between 76 and 77% (SEM = 3% for KG1a and 3Á5% for K562) in MIA-602-treated cells. For the KG1 cells, the control condition showed 1% apoptosis (SEM = 0Á3%)-similar to the other cell lines when untreated-but the MIA-602 treatment control showed only 12% (SEM = 2%).
To confirm the efficacy of treatment with GHRH antagonist in vivo, the cell lines were xenografted by s.c. injection into athymic nude mice. Western blot analysis and immunohistochemistry of tumours from untreated animals showed that GHRH ligand was expressed in all tumours, with the highest levels in K-562 and KG-1a tumours, while in THP-1 and KG-1 tumours the SV1 receptor was absent. p-GHRH-R was detected in KG-1 cells by Western blot, but not by immunohistochemical analysis. The presence of pGHRH-R in KG-1 tumours suggests that the tumour microenvironment is able to induce the expression of GHRH receptors or that the migration/infiltration of GHRH receptor positive cells into the tumours took place. MIA-602 was administered s.c. for 30 days at a dose of 10 lg b.i.d. Therapy with MIA-602 significantly (P < 0Á05) decreased the final volume of K-562, THP-1 and KG-1a tumours by 54%, 42% and 41%, respectively, and prolonged the tumour doubling time (Fig 3, Table I ), but no changes occurred in KG-1 tumour volume. No significant differences in body weights or weights of various organs (liver, spleen, kidneys) were observed between treated animals and those bearing no tumours. Macroscopic observation of organs further revealed no differences after treatment with MIA-602.
Finally, to assess the translational applicability of these results, primary cell samples from AML patients were analysed for the expression of GHRH-R. Immunofluorescent staining on the mononuclear cells indicated positive expression of GHRH-R in all samples (Fig 4A) . Western blotting similarly showed positive expression of the pituitary type of GHRH receptor on 9/9 samples from AML patients (mostly only in the non-glycosylated form), as well as expression of the SV1 receptor variant in 8/9 samples (Fig 4B) .
Discussion
These results provide strong support for an approach to AML treatment based on targeting of GHRH-R. MIA-602 and other GHRH antagonists of the latest series of analogues have been shown to inhibit the growth, tumourigenicity and metastases of various human experimental cancers, through an action exerted on GHRH receptors Rick et al, 2012; Gan et al, 2016; Zarandi et al, 2017) . We demonstrate here the expression of GHRH receptors on both the model AML cell lines THP1, K562, and KG-1a and in the bone marrow cells of patients with AML. These results further demonstrate that the inhibition of proliferation of leukaemic cells in vitro and of tumour growth in a preclinical mouse model, based on the presence of GHRH-R or its SV, is therapeutically relevant in terms of clinical applicability. It is worth noting that, although all patient samples examined were positive for GHRH-R, the level of expression varied between patients. For this reason, further studies are necessary to fully examine the expression of GHRH receptors in the AML patient population, as well as any variance in expression levels between genetic subtypes of AML, to determine how GHRH targeting might be best applied as therapy. The four cell lines chosen are commonly used in cellulo models of AML, each representing a different form of AML. The THP1 cell line originated from the peripheral blood of a patient with acute monocytic leukaemia, KG-1 from the bone marrow of a patient with AML, KG-1a from the in vitro dedifferentiation of the KG-1 line, and the K562 line originated from the pleural effusions of a chronic myeloid leukaemia patient in blast crisis. Among these cell lines, our results showed a diversity of expression of GHRH-R and its subtypes, and a corresponding variability in responses to MIA-602 treatment. It is reasonable to assume that AML subtypes within the patient population may display similar variability in GHRH-R expression. Given the limited scope of established cell lines, further studies are needed to determine the differential GHRH-R expression and, therefore, potential responsiveness to treatment with GHRH antagonists, of the major AML subtypes.
Furthermore, these data indicate that MIA-602 reduces the proliferation of human myeloid leukaemic cell lines by upregulating pro-apoptotic genes, such as CAS9 and TNF, and by inactivation of Akt. These results are consistent with previous findings demonstrating that MIA-602 and the related antagonist MIA-690 trigger apoptosis in human retinoblastoma cells breast cancers and glioblastomas (Chu et al, 2016; Zarandi et al, 2017) . Thus, the anti-proliferative effect of GHRH antagonist MIA-602 could be mediated by inactivation of Akt, which in turn promotes cell apoptosis. Akt regulates cellular apoptosis through the phosphorylation and inhibition of pro-apoptotic members of the BCL2 protein family (Fuchs & Steller, 2011) .
The repressive effects of these analogues on tumours appear to be due to the inhibition of the pituitary GH/hepatic insulin like growth factor 1 (IGF1) axis, suppression of autocrine production of IGF1 in tumours, and the blocking of the action of tumoural GHRH ; however, the inhibition of binding, and hence of the action of autocrine GHRH produced in tumours and the downregulation of GHRH receptors are most likely to constitute the main effects of GHRH antagonists (Zarandi et al, 2017) . MIA-602 has been also shown to decrease Pak1-mediated phosphorylation of both phosphorylated (p)STAT3 and p65 in gastric cancer cell lines and xenografted tumours (Gan et al, 2016) . This effect on Pak1-Stat3/NF-kB signalling may underlie the pro-apoptotic effects on AML cell lines observed in this study and is consistent with the observed inactivation of Akt.
Our study reports a novel approach to the treatment of AML based on antagonists of GHRH. The targeted nature of this approach has the advantage of involving minimal toxicity in contrast to the risks associated with chemotherapy and transplantation. GHRH antagonists could be also used in combination with chemotherapeutic agents to augment their anti-tumour effects (Pinski et al, 1995; Schally, 2008; Schally et al, 2008; Zarandi et al, 2017) . Attempts have been made previously to create targeted therapies for AML, focused on aberrations in the receptor tyrosine kinase FLT3 (Daver & Cortes, 2013; Coombs et al, 2016) , but none of these approaches significantly altered the clinical therapy of AML. Thus, there remains a need for the development of new treatments for AML. This novel strategy, based on antagonists of GHRH targeted to GHRH-R, could provide a useful approach to AML, either alone or in combination with traditional intervention. Table I . Effects of therapy with GHRH antagonist MIA 602 at a dose of 10 lg twice daily on the growth of K-562, THP-1, KG-1a and KG-1 tumours xenografted into nude mice. -9) . Demographics data for these patients is indicated in (C). The AML of each patient was classified according the updated World Health Organisation classification of hematological malignancies (Arber et al, 2016) : 1 -AML with t(9;11)(p22;q23) MLLT3-KMT2A and t(4;15)(p31;q22) TMEM154-RASGRF1; 2 -AML with IDH1 (132R/C) and DNMT3A mutations; 3 -AML minimally differentiated with trisomy 13; 4 -AML with NRAS and TET2 mutations, 5 -AML with NPM1 mutation; 6 -AML with FLT3-internal tandem duplication; 7 -AML with NRAS mutation; 8 -AML with IDH2 (140R/Q) mutation; 9 -AML with CSF3R and TET2 mutations.
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